Billion-dollar autoimmune drug deal a ‘dream come true’ for Calgary researcher

With autoimmune diseases, the body’s own tissues are mistaken for harmful invaders and attacked

Dr. Pere Santamaria, a professor in the Department of Microbiology, Immunology and Infectious Diseases, and member of the university’s Snyder Institute for Chronic Diseases, poses in this undated handout photo. Parvis Therapeudics, the company Santamaria founded, and California-based company Genetech have reached a billion-dollar deal to develop a potential treatment for celiac disease, irritable bowel syndrome and other autoimmune diseases. THE CANADIAN PRESS/HO - University of Calgary, Riley Brandt

A University of Calgary researcher says he’s hopeful a deal worth up to $1 billion between his drug company and a U.S. biotechnology firm could one day lead to autoimmune disease treatments that don’t make patients more vulnerable to infections or cancer.

“It’s kind of a dream come true that I can play a role in this process and realize something that might perhaps help a lot of people,” said Pere Santamaria, founder of Parvus Therapeutics and a professor at the university’s Cumming School of Medicine.

Parvus announced a working and licensing agreement Thursday with California-based Genentech to develop, manufacture and commercialize a class of drugs known as Navacims to potentially treat celiac, autoimmune liver and inflammatory bowel diseases.

Parvus is to get an upfront payment from Genentech and further payments as certain milestones are reached. The companies are not disclosing precisely how the funds are to be broken down or over what time period. Parvus is also eligible to get royalty payments on sales that result from the deal.

READ MORE: Legalization sparks boom in field of marijuana research

The immune system is meant to protect the body from bacteria, viruses and cancer. But in people with autoimmune diseases, the body’s own tissues are mistaken for harmful invaders and attacked.

Current treatments work by suppressing the immune system as a whole, which makes patients less able to fight off infections and cancer.

Navacims, discovered by Santamaria and his team in 2004, use nanoparticles to switch off autoimmune attacks in a way that doesn’t compromise the body’s overall disease-fighting abilities.

Santamaria said the treatments have been tested extensively in mice with promising results. The deal with Genentech will go toward clinical trials in humans. Parvus will be responsible for initial small-scale tests. Genentech will take on subsequent studies in larger groups and, if successful, the regulatory work needed to bring the drug to market.

The companies aren’t disclosing when the trials will be done, but Santamaria said time is of the essence.

“It’ll take some time, but resources will be brought to bear so that this can be accelerated as fast as we can to get these drugs to patients in need.”

Parvus teamed up with another drug firm, Novartis, in 2017 to develop Navacims as a potential treatment for Type 1 diabetes.

Santamaria said bringing Navacims to market without the resources and know-how from larger partners would be inconceivable.

“It’s been a tough, long haul with a lot of challenges and hurdles in many aspects.”

University of Calgary president Ed McCauley said the big-ticket investment affirms how important it is to invest in fundamental research.

“It’s incredible,” he said. “The discoveries we are making are actually being mobilized to help society.”

Lauren Krugel, The Canadian Press

Like us on Facebook and follow us on Twitter

Just Posted

‘No Stone Left Alone’ returns to Wetaskiwin Nov. 2

Volunteers needed for poignant remembrance event

Wetaskiwin’s Horses of Hope event raised over $50,000

Organizers note 160 people attended charity dinner

Military posers insult real veterans: writer

Fake medals and bogus insignia insulting to service members

Two subdivisions given County of Wetaskiwin extensions

Both applicants given 12 month extensions to developments

Suspect wearing Batman cap sexually assaults woman on Main Street Wetaskiwin

Wetaskiwin RCMP Investigate Sexual Assault – Seek Information and ID suspect

Scheer, Trudeau, Singh haggle over potential minority government outcome

If you believe the polls, it appears the Liberals and Conservatives are neck-and-neck

‘The more you test, the more you find’: Beef recalls a sign of success, experts say

Despite appearances, experts say a recent rise in major recalls is not a sign of food supply problems

PODCAST: Journalism instructor discusses how reporters have taken on climate change

Mount Royal University’s Sean Holman has been researching how journalists have covered climate change

ELECTION 2019: Have Justin Trudeau’s Liberals really cut middle-class taxes?

Conservative Andrew Scheer vows to cut bottom bracket, NDP’s Jagmeet Singh targets wealth tax

Alberta truck convoy plans counter-protest at climate rally with Greta Thunberg

United We Roll organizer says similar protest planned for Swedish teen’s event in Edmonton

Maskwacis RCMP truck rammed by fleeing vehicle

An individual has been arrested following a chase and then a deliberate… Continue reading

Alberta takes second look at trucking changes after meeting Broncos families

Transportation minister has said government was reviewing rules for school bus drivers and farmers

Male pedestrian dead after collision with train in Blackfalds

Man from Red Deer pronounced dead at the scene

‘Sky didn’t fall:’ Police, lawyers still adjusting after pot legalization

Statistics Canada says 541 people were charged under the federal Cannabis Act between Oct. 17, 2018 and the end of the year

Most Read